World Business Watch
GLOBAL BUSINESS INTELLIGENCE FOR DECISION MAKERS
Monday, 9 November 2026
worldbusinesswatch.com

NEWS | HEALTHCARE & LIFE SCIENCES

Novo Nordisk lifts 2026 outlook as Wegovy pill sales hit DKK 5.4B

Novo beat expectations and raised its guidance for the second time this year on strong demand for its weight-loss pill. Its shares jumped more than 6% in early trading.

By **Manasee Kurlekar** | November 4, 2026



Novo beat expectations and raised its guidance for the second time this year on strong demand for its weight-loss pill. Its shares jumped more than 6% in early trading.

Q3 adjusted operating profit rose 27% at constant currencies to DKK 31.7B. Wegovy pill sales reached DKK 5.39B, and the pill is now launched in eight markets.

Novo now sees 2026 adjusted sales and operating profit between -2% and +2%, up from -6% to 0%. Reported operating profit fell 9% on DKK 8.7B of impairments, and

Novo plans to cut US list prices for Wegovy and Ozempic to $675 from 1 Jan 2027.

Read online: https://worldbusinesswatch.com/news/14/369/novo-nordisk-lifts-2026-outlook-as-wegovy-pill-sales-hit-dkk-5-4b.html
© 2026 World Business Watch. All rights reserved.